AI in Drug Discovery Market
AI in Drug Discovery Market by Process (Target, Lead), Use Case (Repurposing, DE Novo Drug Design [Vaccine] Optimization, Disease Understanding, PK/PD), Therapy (Cancer, CNS), Tool (DL [CNN, GAN]), End User - Global Forecast to 2031
AI IN DRUG DISCOVERY MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global AI in drug discovery market is projected to grow from USD 5.09 billion in 2026 to USD 17.56 billion by 2031, at a CAGR of 28.1% during the forecast period. The market was valued at USD 3.92 billion in 2025. The market is driven by growing pharmaceutical demand to reduce drug discovery timelines and R&D costs, increasing adoption of generative AI and foundation models, expanding availability of multi-omics datasets, and investments in AI-enabled drug discovery platforms. Increasing strategic collaborations between pharmaceutical companies and AI technology providers, coupled with advances in cloud computing, high-performance computing, and computational biology, are further boosting the adoption of AI across early-stage drug discovery.
KEY TAKEAWAYS
-
MARKET SNAPSHOT:
Base Year Market Size (2025): USD 3.92 Billion
Current Market Size (2026): USD 5.09 Billion
Forecast Market Size (2031): USD 17.56 Billion
CAGR (2026–2031): 28.1% -
SEGMENT LEADERSHIP:
Regional Leader: North America accounted for a 44.9% share of the AI in drug discovery market in 2025.
Process Leader: Hit-to-lead identification/lead generation segment is expected to register the highest CAGR between 2026 and 2031.
Use Case Leader: De novo drug design segment is projected to grow at the fastest rate from 2026 to 2031.
Therapeutic Area Leader: Oncology segment held the largest share of 38.6% in 2025.
Player Type Leader: AI technology providers segment is projected to grow at the fastest rate from 2026 to 2031.
AI Tool Leader: Machine learning segment is expected to dominate the market during the forecast period.
Deployment Model Leader: Cloud-based model is projected to exhibit a CAGR of 28.7% during the forecast period.
End User Leader: Pharmaceutical & biotechnology companies segment accounted for the largest share in the AI in drug discovery market in 2025. -
MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
NVIDIA Corporation, Schrodinger, Inc., and Recursion were identified as some of the star players in the AI in drug discovery market, given their strong market share and product footprint.
Xaira Therapeutics, Inc., Converge Bio, and CellType Inc., among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.
The AI in drug discovery market is undergoing a fundamental shift from hypothesis-driven research to data-driven drug discovery, enabling researchers to identify novel biological targets, predict molecular interactions, and prioritize high-potential drug candidates with greater confidence. AI is enabling pharmaceutical companies to integrate diverse datasets spanning genomics, proteomics, transcriptomics, scientific literature, and real-world evidence, improving decision-making throughout the discovery pipeline. As AI models become increasingly predictive and scalable, organizations are adopting AI as a core component of early-stage drug discovery to enhance portfolio quality, increase research productivity, and improve the probability of successful therapeutic development.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The AI in drug discovery market is evolving from fragmented, stage-specific applications toward integrated discovery ecosystems that connect biological data, computational chemistry, and experimental validation within a unified workflow. Pharmaceutical companies are increasingly adopting AI platforms to improve decision-making across the discovery pipeline, enabling faster prioritization of drug candidates and more informed portfolio management. This transition from isolated AI tools to enterprise-scale discovery platforms is reshaping technology investments and positioning AI as a strategic capability for next-generation pharmaceutical innovation.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Rising need to reduce time and cost of drug discovery and development
-
Growing utilization of AI to predict drug-target interactions for cancer therapy
Level
-
Shortage of AI workforce and regulatory frameworks for AI-enabled drug discovery
-
Increasing AI compute infrastructure costs amid global HBM/DRAM/NAND shortage
Level
-
Accelerating biotech drug discovery
-
AI-driven single-cell analysis for biomarker and disease-subtype identification
Level
-
Limited availability of high-quality training datasets
-
Limited real-world clinical validation of AI-derived drug candidates
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Rising need to reduce time and cost of drug discovery and development
The rising need to reduce the time and cost associated with drug discovery and development is a major factor driving the adoption of AI in drug discovery. Developing a new medicine remains a lengthy, resource-intensive process, with high attrition rates across the development pipeline. According to PhRMA, bringing a new medicine to market takes an average of 10–15 years and costs approximately USD 2.6 billion, including the cost of failed drug candidates, while only 12% of new molecular entities entering clinical trials ultimately receive FDA approval. These challenges have accelerated the adoption of AI to improve target identification, optimize lead compounds, and prioritize promising drug candidates with greater speed and accuracy. By reducing reliance on iterative laboratory experimentation and improving decision-making during early-stage research, AI enables pharmaceutical companies to enhance R&D productivity, shorten discovery timelines, and improve the probability of successful drug development.
Restraint: Shortage of AI workforce and regulatory frameworks for AI-enabled drug discovery
The shortage of professionals with expertise spanning artificial intelligence, computational biology, medicinal chemistry, and drug discovery remains a significant challenge for the widespread adoption of AI in pharmaceutical R&D. Successful implementation of AI platforms requires multidisciplinary teams capable of developing, validating, and interpreting complex AI models while integrating them into existing drug discovery workflows. At the same time, regulatory frameworks governing the use of AI-generated evidence in drug discovery continue to evolve, creating uncertainty around model validation, transparency, reproducibility, and regulatory acceptance. According to the World Economic Forum's Future of Jobs Report 2025, the demand for AI and big data specialists is expected to grow by over 80% by 2030, making them among the fastest-growing job categories globally. However, the limited availability of professionals with combined expertise in AI and life sciences, coupled with evolving regulatory expectations from agencies such as the US FDA and EMA regarding AI-enabled drug development, may slow technology adoption and increase implementation complexity for pharmaceutical companies.
Opportunity: Accelerating biotech drug discovery
The expanding adoption of AI across biotechnology companies presents a significant growth opportunity for the AI in drug discovery market. Unlike large pharmaceutical companies, many biotechnology firms are AI-native or are rapidly integrating AI to accelerate target identification, de novo drug design, biomarker discovery, and lead optimization while operating with leaner R&D budgets. According to the Biotechnology Innovation Organization (BIO), emerging biotechnology companies account for approximately 70% of the global drug development pipeline, highlighting their growing role in pharmaceutical innovation. AI enables these companies to rapidly validate biological hypotheses, prioritize high-value drug candidates, and advance promising assets into preclinical development with greater efficiency. Increasing investments in AI-native biotechnology startups, expanding collaborations with pharmaceutical companies, and growing availability of cloud-based AI platforms are expected to further accelerate AI adoption across the biotechnology sector, creating substantial growth opportunities for AI technology providers during the forecast period.
Challenge: Limited availability of high-quality training datasets
The limited availability of high-quality, diverse, and well-annotated biological datasets remains a significant challenge for AI in drug discovery market. AI models require access to large volumes of validated genomic, proteomic, chemical, clinical, and real-world data to generate reliable predictions across target identification, molecular design, and lead optimization. However, much of this data remains fragmented across pharmaceutical companies, academic institutions, and public repositories, with varying formats, quality standards, and accessibility. Proprietary data ownership, privacy concerns, and intellectual property restrictions further limit data sharing and model development. According to the OECD's 2024 report, limited access to high-quality, interoperable scientific datasets is one of the primary barriers to developing robust AI models across scientific disciplines, including biomedical research. Addressing these data quality and interoperability challenges will be essential to improving the accuracy, reproducibility, and scalability of AI-enabled drug discovery solutions.
AI IN DRUG DISCOVERY MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
GPU-accelerated computing, BioNeMo foundation models, generative AI, molecular simulation, and high-performance computing platforms supporting target discovery, protein engineering, molecular design, and virtual screening | Faster AI model training | Accelerated molecular discovery | Reduced computational time | Scalable drug discovery workflows | Improved research productivity |
 |
Physics-based molecular modeling, computational chemistry, AI-assisted drug design, virtual screening, and lead optimization through an integrated computational drug discovery platform | Higher prediction accuracy | Improved lead optimization | Lower experimental costs | Accelerated candidate selection | Increased probability of clinical success |
 |
Generative AI-powered target identification, de novo molecule generation, biomarker discovery, and end-to-end drug discovery through the Pharma.AI platform integrating biology, chemistry, and clinical data | Shortened discovery timelines | Rapid identification of novel drug candidates | Improved target validation | Enhanced R&D efficiency | Reduced drug development costs |
 |
AI-driven phenomics platform combining high-content cellular imaging, machine learning, automated experimentation, and large-scale biological datasets for target discovery and therapeutic development | Faster target identification | Improved biological insights | Higher-quality candidate selection | Increased experimental throughput | Enhanced translational research efficiency |
 |
AI foundation models, protein structure prediction, cloud-based AI infrastructure, and multimodal data analytics supporting drug target discovery, molecular modeling, and biomedical research | Improved biological understanding | Accelerated target discovery | Scalable AI infrastructure | Enhanced predictive modelling | Faster scientific innovation |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The AI in Drug Discovery market operates within a collaborative ecosystem comprising pharmaceutical companies, biotechnology firms, AI technology providers, contract research organizations (CROs), academic and research institutions, cloud service providers, and regulatory agencies. Increasing convergence of artificial intelligence, computational biology, high-performance computing, and multi-omics research is accelerating innovation across the drug discovery value chain. Strategic collaborations between AI platform developers and pharmaceutical companies are enabling the development of scalable, data-driven discovery platforms, while advances in cloud computing and laboratory automation are supporting the transition toward integrated and AI-native drug discovery workflows.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
AI in Drug Discovery Market, By Process
Based on process, the hit-to-lead identification/lead generation segment accounted for the largest share of the AI in drug discovery market in 2025. The segment's dominance is driven by the increasing adoption of AI-powered virtual screening, molecular property prediction, and generative chemistry tools that enable rapid identification and optimization of promising lead compounds. By analyzing vast chemical libraries and integrating biological, structural, and pharmacological data, AI significantly improves the quality of lead candidates while reducing the need for resource-intensive laboratory screening. Recent advancements in machine learning and generative AI have further enhanced the efficiency of hit-to-lead workflows, enabling pharmaceutical and biotechnology companies to accelerate early-stage drug discovery, improve candidate success rates, and optimize R&D productivity.
AI in Drug Discovery Market, By Use Case
In 2025, the de novo drug design segment accounted for the largest share of the AI in drug discovery market. This dominance is driven by the increasing adoption of generative AI, deep learning, and computational chemistry platforms that enable the design of novel molecules with desired biological and physicochemical properties. AI-powered de novo drug design significantly accelerates the identification and optimization of potential drug candidates by exploring vast chemical spaces beyond conventional compound libraries. The growing integration of generative models with molecular simulation, structure-based drug design, and predictive analytics has further enhanced the efficiency and success of early-stage drug discovery. As pharmaceutical and biotechnology companies increasingly invest in AI-native drug discovery platforms, de novo drug design continues to play a pivotal role in accelerating innovation and improving R&D productivity.
AI in Drug Discovery Market, By Therapeutic Area
In 2025, the oncology segment accounted for the largest share of the AI in drug discovery market. This dominance is driven by the increasing global cancer burden, extensive oncology drug development pipelines, and the growing adoption of AI to accelerate the discovery of targeted therapies and immuno-oncology drugs. AI enables researchers to analyze complex genomic, transcriptomic, proteomic, and clinical datasets for biomarker identification, target discovery, patient stratification, and lead optimization. The availability of large-scale oncology datasets, coupled with substantial pharmaceutical investments in precision oncology, has further accelerated AI adoption across cancer research. As the demand for personalized cancer therapies continues to grow, oncology is expected to remain the leading therapeutic area in the AI in drug discovery market.
AI in Drug Discovery Market, By Player Type
By player type, the end-to-end solution providers segment accounted for the largest share of the AI in drug discovery market in 2025. The segment's leadership is driven by the growing demand for integrated AI platforms that support the entire drug discovery workflow, from target identification and hit discovery to lead optimization and candidate selection. Pharmaceutical and biotechnology companies increasingly prefer comprehensive solutions that combine artificial intelligence, computational chemistry, multi-omics data integration, molecular modeling, and predictive analytics within a unified platform. These end-to-end platforms improve workflow efficiency, reduce integration complexity, and enable seamless data exchange across discovery stages. As organizations continue to consolidate technology vendors and adopt enterprise-wide AI strategies, end-to-end solution providers are expected to maintain their leading position in the AI in drug discovery market.
AI in Drug Discovery Market, By AI Tool
By AI tool, the machine learning segment is expected to dominate the AI in drug discovery market, registering the highest CAGR during the forecast period. The segment is driven by the widespread application of machine learning algorithms across target identification, virtual screening, molecular property prediction, hit prioritization, and lead optimization. Machine learning enables rapid analysis of large-scale biological, chemical, and multi-omics datasets, improving the accuracy of predictive models while reducing reliance on time-intensive experimental approaches. Continuous advancements in deep learning, graph neural networks, and generative AI are further expanding the capabilities of machine learning in molecular design and drug candidate optimization. As pharmaceutical and biotechnology companies increasingly integrate AI into their discovery workflows, machine learning is expected to remain the fastest-growing AI tool in the AI in drug discovery market.
AI in Drug Discovery Market, By Deployment Model
By deployment model, the cloud-based deployment segment accounted for the largest share of the AI in drug discovery market in 2025. The segment's dominance is driven by the increasing demand for scalable computing infrastructure capable of supporting AI model training, molecular simulations, and the analysis of large-scale biological and chemical datasets. Cloud-based platforms enable pharmaceutical and biotechnology companies to securely store, process, and share research data while facilitating collaboration across geographically distributed R&D teams. In addition, cloud deployment provides flexible access to high-performance computing resources, reducing infrastructure costs and accelerating AI-driven drug discovery workflows. As organizations continue to adopt cloud-native research environments and integrate AI across the drug discovery pipeline, cloud-based deployment is expected to maintain its leading position in the market.
AI in Drug Discovery Market, By End User
By end user, the pharmaceutical & biotechnology companies segment accounted for the largest share of the AI in drug discovery market in 2025. The segment's dominance is driven by increasing investments in AI-enabled drug discovery platforms to accelerate target identification, lead optimization, and candidate selection while improving R&D productivity. Pharmaceutical and biotechnology companies are leveraging AI to analyze complex biological and chemical datasets, enhance predictive modeling, and reduce dependence on conventional trial-and-error approaches in early-stage drug discovery. The growing need to improve pipeline productivity, address rising R&D costs, and accelerate the development of novel therapeutics has further increased the adoption of AI across pharmaceutical research. As AI becomes an integral component of modern drug discovery strategies, pharmaceutical and biotechnology companies are expected to remain the largest end users of AI-driven drug discovery solutions.
REGION
Asia Pacific to be fastest-growing region in AI in drug discovery market
Asia Pacific is the fastest-growing AI in drug discovery market, supported by the rapid expansion of pharmaceutical and biotechnology research, increasing availability of genomic and clinical datasets, and growing investments in AI-native drug discovery companies. The region is emerging as a global hub for computational drug discovery, driven by expanding cloud infrastructure, high-performance computing capabilities, and a strong pipeline of AI-enabled biotechnology startups. China, Japan, South Korea, Singapore, and India are witnessing increasing adoption of AI across target identification, molecular design, and lead optimization, while collaborations between regional biotechnology companies and global pharmaceutical manufacturers continue to accelerate technology commercialization. These factors are positioning the region as a key growth engine for AI-enabled drug discovery during the forecast period.
AI IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX
NVIDIA Corporation (Star) holds a leading position in the AI in drug discovery market through its accelerated computing platforms, BioNeMo foundation models, and GPU-optimized AI ecosystem that power molecular simulation, predictive modeling, virtual screening, and generative drug design. Its strong collaborations with pharmaceutical companies, biotechnology firms, and research institutions, coupled with continued investments in high-performance computing and agentic AI, reinforce its leadership in enabling scalable AI-driven drug discovery. Microsoft Corporation (Emerging Leader) is rapidly strengthening its market presence through Azure AI, cloud-native infrastructure, and advanced AI development services that support large-scale biological data integration, AI model training, target identification, and collaborative drug discovery. The company's expanding partnerships across the pharmaceutical and life sciences ecosystem position it as a key enabler of next-generation AI-powered therapeutics and digital R&D transformation.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- NVIDIA Corporation (US)
- Schrödinger, Inc. (US)
- Microsoft Corporation (US)
- Recursion (US)
- Insilico Medicine (US)
- Google (US)
- BenevolentAI (UK)
- Numerion Labs (US)
- Illumina, Inc. (US)
- XtalPi Inc. (China)
- Iktos (France)
- Tempus AI, Inc. (US)
- Deep Genomics, Inc. (Canada)
- Verge Labs (US)
- BPGbio, Inc. (US)
- BenchSci (Canada)
- Valo Health (US)
- insitro (US)
- Relay Therapeutics (US)
- Generate:Biomedicines (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 3.92 Billion |
| Market Size in 2026 (Value) | USD 5.09 Billion |
| Market Forecast in 2031 (Value) | USD 17.56 Billion |
| CAGR | 28.1% |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa |
WHAT IS IN IT FOR YOU: AI IN DRUG DISCOVERY MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Map the AI in drug discovery ecosystem | Comprehensive ecosystem mapping across pharmaceutical companies, biotechnology firms, AI technology providers, CROs, academic & research institutes, cloud providers, regulators, and data providers | Provides clear visibility into the market ecosystem and value chain, enabling strategic partnership, investment, and ecosystem expansion decisions |
| Understand AI integration across the drug discovery value chain | In-depth analysis of AI adoption across target identification, hit discovery, lead optimization, candidate selection, data integration, cloud deployment models, and computational biology platforms | Reduces technology adoption risk and supports AI roadmap development aligned with pharmaceutical R&D priorities |
| Identify high-growth AI use cases across drug discovery | Prioritized assessment of AI applications across disease understanding, drug repurposing, de novo drug design, drug optimization, and preclinical testing | Enables focused product development, technology investments, and commercialization strategies in high-growth applications |
| Benchmark competitors in the AI in drug discovery landscape | Competitive benchmarking of leading AI drug discovery companies | Strengthens competitive positioning, identifies technology gaps, and uncovers whitespace opportunities for differentiation |
| Assess regulatory, data governance, and commercialization trends | Analysis of evolving AI governance frameworks, data privacy requirements, intellectual property considerations, AI validation practices, and pharmaceutical regulatory trends influencing AI adoption | Supports regulatory readiness, risk mitigation, and commercialization strategies while improving long-term market competitiveness |
RECENT DEVELOPMENTS
- July 2026 : Insilico Medicine and Takeda Pharmaceutical entered a strategic AI-driven drug discovery collaboration valued at up to USD 600 million to discover and develop novel therapeutics across multiple disease areas using Insilico's Pharma.AI platform.
- June 2026 : Insilico Medicine and SK Biopharmaceuticals announced a strategic collaboration worth up to USD 2.5 billion to leverage AI for the discovery of novel therapies targeting neuroimmune disorders, combining Insilico's AI platform with SK Biopharmaceuticals' neuroscience expertise.
- March 2026 : NVIDIA Corporation introduced next-generation BioNeMo foundation models and agentic AI capabilities at GTC 2026, enabling pharmaceutical and biotechnology companies to accelerate molecular design, protein engineering, target discovery, and AI-driven drug development workflows.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
The study involved significant activities in estimating the current size of the AI in drug discovery market. Exhaustive secondary research was done to collect information on the market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the AI in drug discovery market.
Secondary Research
This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and Companies House documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in drug discovery solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.
Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in drug discovery vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.
Primary Research
In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources are mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.
Primary research was conducted to identify segmentation types; industry trends; key players; and key market dynamics such as drivers, restraints, opportunities, challenges, industry trends, and strategies adopted by key players. After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at.
In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.
Breakdown of the Primary Respondents:
Note: Other designations include sales managers, marketing managers, and product managers.
Note: Tiers are defined based on a company’s total revenue as of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (revenue share analysis of leading players) and the top-down approach (assessment of utilization/adoption/penetration trends by offering, function, application, deployment, tools, end user, and region).
AI in Drug Discovery Market : Top-Down and Bottom-Up Approach
Data Triangulation
After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the AI in drug discovery market.
Market Definition
The AI in drug discovery market comprises artificial intelligence-based software platforms and computational solutions that accelerate early-stage drug discovery by enabling target identification, lead optimization, candidate selection, and drug repurposing. These solutions leverage technologies such as machine learning, deep learning, and generative AI to improve R&D efficiency, reduce costs, and shorten drug development timelines.
Key Stakeholders
- AI in drug discovery software vendors
- AI in drug discovery service providers
- Pharmaceutical companies
- Biotechnology companies
- AI technology providers
- Drug discovery software providers
- Contract Research Organizations (CROs)
- Academic and research institutes
- Clinical research organizations
- Cloud service and high-performance computing (HPC) providers
- Genomics and multi-omics data providers
- Healthcare data and bioinformatics companies
- Government agencies and regulatory authorities
- Venture capital firms and strategic investors
- Healthcare and life sciences consulting firms
- Contract Development and Manufacturing Organizations (CDMOs)
- Healthcare providers (involved in translational research)
- Precision medicine and companion diagnostics companies
- Life sciences distributors and technology integrators
Report Objectives
- To describe and forecast the global AI in drug discovery market, by process, use case, therapeutic area, player type, AI tool, deployment model, end user, and region, in terms of value
- To provide detailed information regarding the factors such as the drivers, restraints, opportunities, and challenges influencing the growth of the market
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall AI in drug discovery market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the AI in drug discovery market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa, in terms of value
- To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies in the market
- To track and analyze competitive developments such as product & service launches, expansions, partnerships, agreements, collaborations, and acquisitions in the AI in drug discovery market
- To benchmark players within the AI in drug discovery market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offering
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
Geographic Analysis
-
Further breakdown of the Rest of Europe’s AI in drug discovery market into Denmark, Norway, and others
-
Further breakdown of the Rest of Asia Pacific AI in drug discovery market into Vietnam, New Zealand, Australia, South Korea, and others
Company Information
-
Detailed analysis and profiling of additional market players (up to 5)
Key Questions Addressed by the Report
- On-premise
- Cloud-based
- SaaS-based
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
- Research Centers, Academic Institutes, & Government Organizations
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the AI in Drug Discovery Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationTESTIMONIALS
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Companywww.sfihealth.com/
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Companywww.qualicaps.com/
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnosticsimaging.bracco.com/us-en
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.www.3m.com/3M/en_US/health-information-systems-us
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Growth opportunities and latent adjacency in AI in Drug Discovery Market
Anthony
Jun, 2022
Which market segment is expected to shape the future of the AI in Drug Discovery Market?.
Adam
Jun, 2022
Which are the most innovative companies in AI in Drug Discovery Market?.
Mathew
Jun, 2022
What are the new trends and advancements in the AI in Drug Discovery Market?.